Literature DB >> 17855708

Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.

Gary M Clifford1, Hai-Rim Shin, Jin-Kyoung Oh, Tim Waterboer, Young-Hee Ju, Salvatore Vaccarella, Wim Quint, Michael Pawlita, Silvia Franceschi.   

Abstract

In the absence of genital samples, human papillomavirus (HPV) serology may be useful to assess HPV infection in young men and women. HPV seroprevalence and determinants of seropositivity were assessed in 817 female and 518 male university students in Busan, South Korea, of whom 74% and 44%, respectively, reported never having had penetrative sexual intercourse. Type-specific HPV DNA status, assessed by a short PCR fragment primer set, was available from genital samples. Seropositivity to L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58 were assessed using multiplex HPV serology. Among women, HPV seroprevalence was significantly higher among sexually active (26.1%) than nonsexually active students [11.1%, odds ratio (OR) = 2.9; 95% confidence interval (95% CI), 1.8-4.7], although the association was weaker than that for HPV DNA prevalence (OR, 14; 95% CI, 4.7-42). Furthermore, HPV seroprevalence was higher among HPV DNA-positive (24%) than HPV DNA-negative women (13%), and there was a positive correlation of type-specific seroprevalence with the presence of HPV DNA of the same type. In contrast, HPV seropositivity among men was not associated with sexual behavior or the presence of HPV DNA. Seroprevalence correlates with genital HPV exposure in young women, but its meaning in young men is unclear.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855708     DOI: 10.1158/1055-9965.EPI-07-0349

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  47 in total

1.  Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.

Authors:  Krystle A Lang Kuhs; Aimée R Kreimer; Sumita Trivedi; Dana Holzinger; Michael Pawlita; Ruth M Pfeiffer; Sandra P Gibson; Nicole C Schmitt; Allan Hildesheim; Tim Waterboer; Robert L Ferris
Journal:  Cancer       Date:  2017-09-26       Impact factor: 6.860

2.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

3.  Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Authors:  Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

5.  Human papillomavirus prevalence and genotype distribution among HIV-infected women in Korea.

Authors:  Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

6.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

7.  Combined effects of smoking and HPV16 in oropharyngeal cancer.

Authors:  Devasena Anantharaman; David C Muller; Pagona Lagiou; Wolfgang Ahrens; Ivana Holcátová; Franco Merletti; Kristina Kjærheim; Jerry Polesel; Lorenzo Simonato; Cristina Canova; Xavier Castellsague; Tatiana V Macfarlane; Ariana Znaor; Peter Thomson; Max Robinson; David I Conway; Claire M Healy; Anne Tjønneland; Ulla Westin; Johanna Ekström; Jenny Chang-Claude; Rudolf Kaaks; Kim Overvad; Dagmar Drogan; Göran Hallmans; Göran Laurell; H B Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Nerea Larrañaga; Ruth C Travis; Domenico Palli; Aurelio Barricarte; Antonia Trichopoulou; Saitakis George; Dimitrios Trichopoulos; J Ramón Quirós; Sara Grioni; Carlotta Sacerdote; Carmen Navarro; María-José Sánchez; Rosario Tumino; Gianluca Severi; Marie-Christine Boutron-Ruault; Francoise Clavel-Chapelon; Salvatore Panico; Elisabete Weiderpass; Eiliv Lund; Inger T Gram; Elio Riboli; Michael Pawlita; Tim Waterboer; Aimée R Kreimer; Mattias Johansson; Paul Brennan
Journal:  Int J Epidemiol       Date:  2016-05-19       Impact factor: 7.196

8.  Determinants of seropositivity among HPV-16/18 DNA positive young women.

Authors:  Carolina Porras; Christina Bennett; Mahboobeh Safaeian; Sarah Coseo; Ana Cecilia Rodríguez; Paula González; Martha Hutchinson; Silvia Jiménez; Mark E Sherman; Sholom Wacholder; Diane Solomon; Leen-Jan van Doorn; Catherine Bougelet; Wim Quint; Mark Schiffman; Rolando Herrero; Allan Hildesheim
Journal:  BMC Infect Dis       Date:  2010-08-11       Impact factor: 3.090

9.  Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Teresa M Darragh; Michael Pawlita; Denise A Galloway; Stephen Shiboski
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

10.  Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women.

Authors:  Yan Tong; Aaron Ermel; Wanzhu Tu; Marcia Shew; Darron R Brown
Journal:  J Med Virol       Date:  2013-07-16       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.